I am not very familiar with French terminology.
The issue of addressing the right to information is important. However, in the context of the example, the position of greatest relevance has been that of addressing issues of health and safety; and an issue of health and safety, as it relates to genetically modified products and the mandatory obligation, could be addressed through labelling. Clearly, if there is a risk related to the product, then that product should not be in the marketplace. However, there are some issues relevant to health for certain sectors of the population that can be communicated quite effectively through labelling. Where such a product would be presented, that information would be required on a mandatory basis.
The ability to provide further information regarding the process by which the product was developed is currently provided for through work undertaken in collaboration with the Canadian General Standards Board in order to provide a standard for the voluntary labelling of products derived from, or not derived from, the techniques of genetic modification or genetic engineering.
It might be useful for me to turn to Carla Barry, who can provide a little more insight in regard to the application of that voluntary standard versus the mandatory requirements as related to health and safety.